CORC

浏览/检索结果: 共6条,第1-6条 帮助

限定条件        
已选(0)清除 条数/页:   排序方式:
Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). 会议论文
作者:  Price, Timothy Jay;  Newhall, Kathryn;  Peeters, Marc;  Kim, Tae Won;  Li, Jin
收藏  |  浏览/下载:2/0  |  提交时间:2019/12/13
Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT 会议论文
作者:  Peeters, Marc;  Price, Timothy Jay;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano
收藏  |  浏览/下载:3/0  |  提交时间:2019/12/13
Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT. 会议论文
作者:  Price, Timothy Jay;  Peeters, Marc;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano
收藏  |  浏览/下载:5/0  |  提交时间:2019/12/13
Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) 会议论文
作者:  Price, Timothy Jay;  Peeters, Marc;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano
收藏  |  浏览/下载:7/0  |  提交时间:2019/12/13
Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). 会议论文
作者:  Price, Timothy Jay;  Newhall, Kathryn;  Peeters, Marc;  Kim, Tae Won;  Li, Jin
收藏  |  浏览/下载:3/0  |  提交时间:2019/12/19
MITOCHONDRIAL OXIDATIVE CAPACITY DURING ANAPHYLACTIC SHOCK IN SENSITIZED-RATS, A PRELIMINARY STUDY 会议论文
作者:  Oulehri, Walid;  Collange, Olivier;  Zheng, Feng;  Tacquard, Charles;  Charles, Anne-Laure
收藏  |  浏览/下载:3/0  |  提交时间:2019/12/05


©版权所有 ©2017 CSpace - Powered by CSpace